لخّصلي

Pathophysiology of Bronchial Asthma:

Bronchial asthma is a chronic inflammatory disease of the airways characterized by hyperresponsiveness, airflow obstruction, and recurrent episodes of wheezing, breathlessness, chest tightness, and coughing.Airway Remodeling:

o	Chronic inflammation leads to structural changes in the airway over time:
o	Smooth muscle hypertrophy and hyperplasia
o	Subepithelial fibrosis (due to deposition of collagen and extracellular matrix)
o	Goblet cell hyperplasia and increased mucus production
o	Thickening of the basement membrane
o	These changes contribute to irreversible airflow limitation in severe or poorly controlled asthma.Airflow Obstruction:

o	Obstruction is caused by a combination of:
o	Bronchial smooth muscle contraction
o	Airway edema
o	Mucus plugging
o	This results in reduced airflow, especially during expiration, causing air trapping and increased work of breathing.Summary:

Asthma is driven by chronic inflammation and immune dysregulation, leading to airway hyperresponsiveness, reversible obstruction, and structural remodeling over time.Airway Inflammation:

o	Chronic inflammation is the hallmark of asthma and is triggered by exposure to allergens, irritants, or infections.o	Inflammatory mediators (e.g., histamine, leukotrienes, prostaglandins) cause bronchoconstriction, vascular leakage, and mucus hypersecretion.o	Chest tightness: Caused by airway narrowing and hyperinflation.2.3.4.5.6.7.:

Pathophysiology of Bronchial Asthma:

Bronchial asthma is a chronic inflammatory disease of the airways characterized by hyperresponsiveness, airflow obstruction, and recurrent episodes of wheezing, breathlessness, chest tightness, and coughing. These episodes are usually reversible, either spontaneously or with treatment. The pathophysiology involves the following key components:

1. 
   

   Airway Inflammation:

   
   

   • Chronic inflammation is the hallmark of asthma and is triggered by exposure to allergens, irritants, or infections.
   • Inflammatory cells like eosinophils, mast cells, T-helper type 2 (Th2) lymphocytes, and neutrophils infiltrate the airway walls.
   • Cytokines (e.g., IL-4, IL-5, IL-13) released by Th2 cells play a central role in promoting inflammation and airway remodeling.
   • Inflammatory mediators (e.g., histamine, leukotrienes, prostaglandins) cause bronchoconstriction, vascular leakage, and mucus hypersecretion.

   
   


2. 
   

   Airway Hyperresponsiveness (AHR):

   
   

   • The inflamed airways become excessively sensitive to various stimuli such as allergens, cold air, exercise, or irritants.
   • This hyperresponsiveness leads to exaggerated bronchoconstriction.

   
   


3. 
   

   Bronchoconstriction:

   
   

   • Constriction of the bronchial smooth muscle is the primary cause of acute airflow obstruction during an asthma attack.
   • Triggered by mediators such as leukotrienes, histamine, and acetylcholine released from mast cells and other inflammatory cells.

   
   


4. 
   

   Airway Remodeling:

   
   

   • Chronic inflammation leads to structural changes in the airway over time:
   • Smooth muscle hypertrophy and hyperplasia
   • Subepithelial fibrosis (due to deposition of collagen and extracellular matrix)
   • Goblet cell hyperplasia and increased mucus production
   • Thickening of the basement membrane
   • These changes contribute to irreversible airflow limitation in severe or poorly controlled asthma.

   
   


5. 
   

   Mucus Hypersecretion:

   
   

   • Increased mucus production, combined with impaired mucociliary clearance, leads to airway plugging and further obstruction.

   
   


6. 
   

   Airflow Obstruction:

   
   

   • Obstruction is caused by a combination of:
   • Bronchial smooth muscle contraction
   • Airway edema
   • Mucus plugging
   • This results in reduced airflow, especially during expiration, causing air trapping and increased work of breathing.

   
   


7. 
   

   Imbalance Between Sympathetic and Parasympathetic Systems:

   
   

   • Enhanced parasympathetic activity leads to bronchoconstriction, while diminished β2-adrenergic receptor activity reduces bronchodilation.

   
   

Clinical Manifestations of Pathophysiology:

•	Dyspnea and wheezing: Due to airway narrowing.

•	Cough: Often worse at night or early morning due to increased airway hyperreactivity.

•	Chest tightness: Caused by airway narrowing and hyperinflation.

•	Prolonged expiration: Due to airflow limitation.

Summary:

Asthma is driven by chronic inflammation and immune dysregulation, leading to airway hyperresponsiveness, reversible obstruction, and structural remodeling over time. This creates a cycle of inflammation, exacerbation, and worsening lung function if untreated. Effective management targets inflammation (e.g., corticosteroids) and bronchoconstriction (e.g., β2-agonists).
: